Claim 1: a cancer treatment method, including combining treatment, such as combined formula or patient alternative formula, in which the treatment combination includes the number of effective taelisib treatment and the number of effective palboccilb treatment； The formula structure (1) and (2) of taelisib and palbocirib,O stereoisomers, geometric isomers, Dow or pharmaceutically acceptable salts. Claim 24: a manufacturing product for cancer treatment, comprising: (a) a treatment combination, wherein there is an effective number of taelisib treatments and an effective number of palboccilb treatments； taelisib and palboccilib have a formula structure (1) and (2),O stereoisomers, geometric isomers, tautometers or pharmaceutically acceptable salts； and (b) instructions for use. Requirement 29: one way to control whether cancer patients will receive treatment is to combine treatment, including effective treatment amount taelisib and effective treatment amount palboccilb； formula structure (1) and (2) of taelisib and palboccilb,o. Stereoisomer, geometric isomer, tautometer or pharmaceutically acceptable salts, including: (a) detection of PIK3CA or PTEN variation in a patient's biological sample after use of at least one dose of taelisib or therapeutic mixture； and (b) comparison； The mutation status of pickup or PTEN was obtained from the biological samples of patients before tasselib administration or combination of patient treatment,In this process, the change or modulation of PIK3CA or PTEN mutation state in samples obtained after using taelisib or treatment combination determines a patient who will respond to treatment through treatment combination. 13. Claim 36: use of mixed therapy, including effective therapeutic amount taelisib and effective therapeutic amount palboccrib； taelisib and palboccrib have formula structures (1) and (2) in them,o. In patients involving a combination of treatment for cancer, stereoisomers, geometric isomers, tautometers, or pharmaceutica
